<DOC>
	<DOC>NCT00216398</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.</brief_summary>
	<brief_title>Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Clinical diagnosis of acromegaly The patient must have been tested at Week 4 (4 weeks prior to the Baseline visit) and shown to have a GH level &lt;10 mU/L. The patient must have been treated with a stable dose of octreotide LAR for at least four months prior to study entry Life expectancy of at least 2 years Adenectomy within past 6 months, or likely during study period Radiotherapy for acromegalic disease within 1 year, or likely during study period Unstable concomitant dopamine agonist therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>acromegaly</keyword>
	<keyword>growth hormone</keyword>
</DOC>